{"id":"W4376107652","doi":"10.1056/nejmoa2212851","title":"Cabozantinib plus Nivolumab and Ipilimumab in Renal-Cell Carcinoma","year":2023,"lang":"en","type":"article","venue":"New England Journal of Medicine","topic":"Renal cell carcinoma treatment","field":"Medicine","cited_by":158,"is_retracted":false,"has_abstract":true,"ca_institutions":"University of Calgary","funders":"Istituto Oncologico Veneto; Institut Gustave-Roussy; Université Paris-Saclay; National Cancer Institute; Cancer Research UK; Dana-Farber/Harvard Cancer Center; Bristol-Myers Squibb; Queen Mary University of London; Exelixis; Memorial Sloan-Kettering Cancer Center; Brigham and Women's Hospital","keywords":"Cabozantinib; Nivolumab; Ipilimumab; Renal cell carcinoma; Medicine; Oncology; Axitinib; Internal medicine; Immunotherapy; Sunitinib; Cancer","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001757703,0.0007323959,0.001966301,0.0004147645,0.0003771679,0.0005790215,0.0006791286,0.0007411583,0.002043572],"category_scores_gemma":[0.001030162,0.0003749518,0.0009260614,0.0003814408,0.0006463964,0.0004945283,0.0002976021,0.001604627,0.0003429132],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0007652522,"about_ca_system_score_gemma":0.001696099,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0009620347,"about_ca_topic_score_gemma":0.002102607,"domain_scores_codex":[0.9993679,0.0003386096,0.00006417001,0.00008821391,0.0000695445,0.00007152601],"domain_scores_gemma":[0.9993384,0.0001586537,0.0001722634,0.00005084449,0.00004367335,0.0002360067],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.8938348,0.02159976,0.003214912,0.001127958,0.001196752,0.00005971327,0.00008768673,0.0008542421,0.01308025,0.0001111765,0.000848874,0.06398397],"study_design_scores_gemma":[0.7458027,0.2414394,0.006828714,0.00005384432,0.0007332781,0.0001133395,0.00002182231,0.0007761216,0.002864522,0.00009915374,0.001251993,0.00001519687],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9931773,0.005113432,0.0001685614,0.000208929,0.0001200757,0.0006030146,0.0001247092,0.0000267389,0.0004572747],"genre_scores_gemma":[0.9954923,0.002332717,0.0005808609,0.0002233117,0.0002059957,0.0005793598,0.0001789316,0.000005277474,0.0004011707],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.002043572,"threshold_uncertainty_score":0.009295702,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.02772866227719734,"score_gpt":0.2713468021366063,"score_spread":0.2436181398594089,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}